Optimize your pharmaceutical portfolio strategy
Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.
As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.
Key benefits:
In Vivo
By William Looney 14 Nov 2022
The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.
Datamonitor Healthcare
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
In Vivo
14 Nov 2022
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
In Vivo
By Jo Shorthouse 14 Nov 2022
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
Datamonitor Healthcare
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topic Cancer
Datamonitor Healthcare
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Datamonitor Healthcare
By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deals
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Datamonitor Healthcare
By Amanda Micklus 20 Jun 2022
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic Cell & Gene Therapy
Datamonitor Healthcare
By Ian Haydock 15 Jun 2022
Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.
In Vivo
02 Mar 2022
Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.
In Vivo
By Alex Shimmings 05 Jan 2022
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
In Vivo
By Ashley Yeo 28 Dec 2021
At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.
In Vivo
By Lucie Ellis-Taitt 22 Nov 2021
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
Pharma Competitive Intelligence
18 Nov 2021
Scrip's team of trusted industry experts bring you the mos critical news and analysis on key commercial topics, from licensing to clinical trials, and competitor activity, around the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.
In Vivo
25 Jan 2023
In Vivo
25 Jan 2023
In Vivo
25 Jan 2023
In Vivo
25 Jan 2023
In Vivo
23 Jan 2023
In Vivo
23 Jan 2023
In Vivo
23 Jan 2023
In Vivo
18 Jan 2023
In Vivo
18 Jan 2023
In Vivo
18 Jan 2023
In Vivo
12 Jan 2023
In Vivo
12 Jan 2023
In Vivo
12 Jan 2023
In Vivo
09 Jan 2023
In Vivo
09 Jan 2023
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: